Events


AMP Europe 2018

Watch Dr. Atil Bisgil from Cukurova University, Turkey talk about expanding to microbiome research with the GeneReader NGS System. He discusses the pressures faced in a laboratory focused on next generation sequencing and research, looking toward the future of high-throughput NGS testing and expanding to microbiome research with the GeneReader.  


EHA 2018

Stop by the QIAGEN booth #1160 at the 23rd EHA Congress from June 14-17, 2018 at Stockholm, where we will be featuring our latest Sample to Insight solutions, from trusted molecular detection to clinical decision support.


2018 ASCO Annual Meeting

We’re excited to attend the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 in Chicago. Learn more.



Webinar: A clinical view on PITX2 DNA methylation in high-risk breast cancer

A webinar program for oncologists and pathologists Thursday, Feb. 22, 2018 at 1:00 p.m. CET Anthracycline-based chemotherapy is the recommended standard-of-care for certain high-risk breast cancer patients including lymph node-positive, estrogen receptor-positive and HER2-negative high-risk breast cancer patients. However, not all patients benefit equally from this chemotherapy. Learn more about a novel, validated marker that… Read article →













QIAGEN’s GeneReader NGS System gains further validation in oncology research applications with new independent performance review data

Studies presented at AMP Global conference in Berlin reaffirm powerful analytical performance and ease of use for the world’s first complete Sample to Insight NGS solution Hilden, Germany, April 3, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced further validation of the GeneReader NGS System with the publication of five new… Read article →


QIAGEN at AMP Global 2017

The inaugural AMP Global Congress on Molecular Pathology, hosted by the Association for Medical Pathologists (AMP), is the event of the year for molecular pathology, diagnostic technologies and research and clinical applications. AMP Global 2017 is the perfect event for QIAGEN to remind and educate the market about our broad menu of Sample to Insight… Read article →


QIAGEN’s NGS solutions highlighted at the annual Congress of the European Society of Pathology

QIAGEN’s broad portfolio of Sample to Insight solutions for NGS were a focus at the QIAGEN booth and industry symposium at this year’s annual Congress of the European Society of Pathology. The XXXI International Congress of the International Academy of Pathology (IAP) and 28th Congress of the European Society of Pathology (ESP) was hosted for… Read article →


QIAGEN at AMP 2016

Join us at AMP for solutions, from trusted molecular detection to clinical decision support The AMP 2016 Annual Meeting is just around the corner, and we’re excited to see you there at the Convention Center in Charlotte, NC, Nov 10—12! Stop by our booth! Come to booth #1119 to explore our products and speak with our… Read article →


QIAGEN at ESMO 2016

Meet us there to discuss how our next-generation oncology solutions can take you from sample to insight! The ESMO_2016_Meeting is just around the corner, and we’re excited to see you there from Oct. 7 – 11 in Copenhagen! Here at QIAGEN, we are proud to be part of the collaborative effort to improve cancer care…. Read article →


QIAGEN is at ECP 2016 in Cologne!

Meet us there to discuss the new NGS solution to cancer research – our Sample to Insight approach! This year the XXXI International Congress of the International Academy of Pathology (IAP) and the 28th Congress of the European Society of Pathology (ESP) is being hosted as a joint venture in Cologne from September 25–29 (see conference… Read article →


QIAGEN forms Lung Cancer Expert Alliance

Hilden, Germany, and Germantown, Maryland, June 2, 2016 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the formation of a global consortium of international lung cancer experts who will advise the company on the design of new next-generation sequencing (NGS) gene panels and associated workflows that target lung cancer-specific mutations. The members… Read article →


QIAGEN launches liquid biopsy workflow for GeneReader NGS System

  Actionable Insights Tumor Panel enables monitoring of cancer biomarkers from plasma samples Hilden, Germany, and Germantown, Maryland, June 1, 2016 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its liquid biopsy workflow for clinical cancer research using QIAGEN’s GeneReader NGS System for next-generation sequencing (NGS). The Actionable Insights… Read article →


QIAGEN partners to develop predictive tests in oncology

Yesterday, we announced that QIAGEN was entering into a licensing and co-development agreement with Therawis Diagnostics GmbH to develop and commercialize predictive assays in oncology. An initial project will be to develop and market PITX2 as a marker to predict effectiveness of anthracycline treatment in triple negative and other high-risk breast cancer patients. See the full press release… Read article →